Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine for Reversal of Neuromuscular Blockade
NCT02909439Phase 4Completed
- Sponsor
- Stony Brook University
- Start
- Nov 2016
- Primary completion
- Nov 2017
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by Stony Brook University. Primary endpoint: Incentive Spirometry, Change From Baseline and Recovery Profile. Started Nov 2016; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT02909439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02909439.